TF and endometriosis: This study demonstrated the feasibility of fVII-conjugated photosensitizer as a method of targeting angiogenic VECs for PDT, supporting TF as an angiogenic-specific target in the PDT treatment of cancer [83] and AMD [105], as well as in ICON, L-ICON, and CAR-NK immunotherapy of pathological angiogenesis-dependent diseases, notably cancer [65,84,85,96,103,107], AMD [95,97], and endometriosis [94,98].